scholarly journals Erratum: CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)

2012 ◽  
Vol 14 (8) ◽  
pp. 762-762
Keyword(s):  
Fabry Disease ◽  
Clinical Observation ◽  
Agalsidase Beta ◽  
Agalsidase Alfa

scholarly journals Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?

2014 ◽  
Vol 17 (1) ◽  
pp. 21-23 ◽  
Author(s):  
Antonio Pisani ◽  
Eleonora Riccio ◽  
Massimo Sabbatini
Keyword(s):  
Fabry Disease ◽  
Agalsidase Beta ◽  
Agalsidase Alfa

Treatment switch in Fabry disease- a matter of dose?

2020 ◽  
pp. jmedgenet-2020-106874
Author(s):  
Malte Lenders ◽  
Peter Nordbeck ◽  
Sima Canaan-Kühl ◽  
Lukas Kreul ◽  
Thomas Duning ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Dose Group ◽  
Clinical Symptoms ◽  
Organ Damage ◽  
Agalsidase Beta ◽  
Disease Epidemiology ◽  
Reduced Dose ◽  
Clinical Events ◽  
Agalsidase Alfa ◽  
Switch Group

BackgroundPatients with Fabry disease (FD) on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in chronic kidney disease epidemiology collaboration-based estimated glomerular filtration rate (eGFR) and a worsened plasma lyso-Gb3 decrease. Hence, the most effective dose is still a matter of debate.MethodsIn this prospective observational study, we assessed end-organ damage and clinical symptoms in 78 patients who had received agalsidase-beta (1.0 mg/kg) for >1 year, which were assigned to continue this treatment (agalsidase-beta, regular-dose group, n=17); received a reduced dose of agalsidase-beta and subsequent switch to agalsidase-alfa (0.2 mg/kg) or a direct switch to 0.2 mg/kg agalsidase-alfa (switch group, n=22); or were re-switched to agalsidase-beta after receiving agalsidase-alfa for 12 months (re-switch group, n=39) with a follow-up of 88±25 months.ResultsNo differences for clinical events were observed for all groups. Patients within the re-switch group started with the worst eGFR values at baseline (p=0.0217). Overall, eGFR values remained stable in the regular-dose group (p=0.1052) and decreased significantly in the re-switch and switch groups (p<0.0001 and p=0.0052, respectively). However, in all groups males presented with an annual loss of eGFR by –2.9, –2.5 and −3.9 mL/min/1.73 m² (regular-dose, re-switch, switch groups, all p<0.05). In females, eGFR decreased significantly only in the re-switch group by −2.9 mL/min/1.73 m² per year (p<0.01). Lyso-Gb3 decreased in the re-switch group after a change back to agalsidase-beta (p<0.05).ConclusionsOur data suggest that a re-switch to high dosage of agalsidase results in a better biochemical response, but not in a significant renal amelioration especially in classical males.

Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta

2008 ◽  
Vol 95 (1-2) ◽  
pp. 114-115 ◽  
Author(s):  
Atul Mehta ◽  
Michael Beck ◽  
Christoph Kampmann ◽  
Andrea Frustaci ◽  
Dominique P. Germain ◽  
...  
Keyword(s):  
Enzyme Replacement Therapy ◽  
Fabry Disease ◽  
Replacement Therapy ◽  
Agalsidase Beta ◽  
Enzyme Replacement ◽  
Agalsidase Alfa

scholarly journals Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study

2018 ◽  
Vol 123 (2) ◽  
pp. S64-S65
Author(s):  
Carla E. Hollak ◽  
Maarten Arends ◽  
Christoph Wanner ◽  
Sandra Sirrs ◽  
Atul Mehta ◽  
...  
Keyword(s):  
Cohort Study ◽  
Fabry Disease ◽  
Agalsidase Beta ◽  
Agalsidase Alfa

Evaluation of glycosphingolipid clearance in patients with Fabry disease treated with agalsidase alfa who switched to agalsidase beta (the INFORM study)

2014 ◽  
Vol 111 (2) ◽  
pp. S24
Author(s):  
John A. Barranger ◽  
Michael J. Gambello ◽  
Ozlem Goker-Alpan ◽  
Gustavo H.B. Maegawa ◽  
Khan J. Nedd ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Agalsidase Beta ◽  
Agalsidase Alfa

Clinical outcomes after switching to migalastat from agalsidase alfa or agalsidase beta in patients with Fabry disease: Post hoc analysis from ATTRACT

2019 ◽  
Vol 126 (2) ◽  
pp. S141
Author(s):  
Gere Sunder-Plassmann ◽  
Ana Jovanovic ◽  
Ulla Feldt-Rasmussen ◽  
Vipul Jain ◽  
Markus Peceny ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Clinical Outcomes ◽  
Agalsidase Beta ◽  
Post Hoc Analysis ◽  
Agalsidase Alfa ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document